Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Galantamine prevents long-lasting suppression of excitatory synaptic transmission in CA1 pyramidal neurons of soman-challenged guinea pigs.

Alexandrova EA, Alkondon M, Aracava Y, Pereira EF, Albuquerque EX.

Neurotoxicology. 2014 Sep;44:270-8. doi: 10.1016/j.neuro.2014.07.005. Epub 2014 Jul 23.

2.

Animal models that best reproduce the clinical manifestations of human intoxication with organophosphorus compounds.

Pereira EF, Aracava Y, DeTolla LJ Jr, Beecham EJ, Basinger GW Jr, Wakayama EJ, Albuquerque EX.

J Pharmacol Exp Ther. 2014 Aug;350(2):313-21. doi: 10.1124/jpet.114.214932. Epub 2014 Jun 6.

3.

Pretreatment of Guinea pigs with galantamine prevents immediate and delayed effects of soman on inhibitory synaptic transmission in the hippocampus.

Alexandrova EA, Aracava Y, Pereira EF, Albuquerque EX.

J Pharmacol Exp Ther. 2010 Sep 1;334(3):1051-8. doi: 10.1124/jpet.110.167700. Epub 2010 Jun 16.

4.

An acute exposure to a sub-lethal dose of soman triggers anxiety-related behavior in guinea pigs: interactions with acute restraint.

Mamczarz J, Pereira EF, Aracava Y, Adler M, Albuquerque EX.

Neurotoxicology. 2010 Jan;31(1):77-84. doi: 10.1016/j.neuro.2009.10.012. Epub 2009 Oct 31.

5.

Magnetic resonance imaging reveals that galantamine prevents structural brain damage induced by an acute exposure of guinea pigs to soman.

Gullapalli RP, Aracava Y, Zhuo J, Helal Neto E, Wang J, Makris G, Merchenthaler I, Pereira EF, Albuquerque EX.

Neurotoxicology. 2010 Jan;31(1):67-76. doi: 10.1016/j.neuro.2009.09.004. Epub 2009 Sep 24.

PMID:
19782102
6.

Effectiveness of donepezil, rivastigmine, and (+/-)huperzine A in counteracting the acute toxicity of organophosphorus nerve agents: comparison with galantamine.

Aracava Y, Pereira EF, Akkerman M, Adler M, Albuquerque EX.

J Pharmacol Exp Ther. 2009 Dec;331(3):1014-24. doi: 10.1124/jpet.109.160028. Epub 2009 Sep 9.

7.

Molecular and cellular actions of galantamine: clinical implications for treatment of organophosphorus poisoning.

Pereira EF, Aracava Y, Alkondon M, Akkerman M, Merchenthaler I, Albuquerque EX.

J Mol Neurosci. 2010 Jan;40(1-2):196-203. doi: 10.1007/s12031-009-9234-3. Epub 2009 Aug 19.

PMID:
19690988
8.

Acute toxicity of organophosphorus compounds in guinea pigs is sex- and age-dependent and cannot be solely accounted for by acetylcholinesterase inhibition.

Fawcett WP, Aracava Y, Adler M, Pereira EF, Albuquerque EX.

J Pharmacol Exp Ther. 2009 Feb;328(2):516-24. doi: 10.1124/jpet.108.146639. Epub 2008 Nov 4.

9.

A single in vivo application of cholinesterase inhibitors has neuron type-specific effects on nicotinic receptor activity in guinea pig hippocampus.

Alkondon M, Aracava Y, Pereira EF, Albuquerque EX.

J Pharmacol Exp Ther. 2009 Jan;328(1):69-82. doi: 10.1124/jpet.108.146068. Epub 2008 Oct 8.

10.

Effective countermeasure against poisoning by organophosphorus insecticides and nerve agents.

Albuquerque EX, Pereira EF, Aracava Y, Fawcett WP, Oliveira M, Randall WR, Hamilton TA, Kan RK, Romano JA Jr, Adler M.

Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13220-5. Epub 2006 Aug 16.

11.

Memantine blocks alpha7* nicotinic acetylcholine receptors more potently than n-methyl-D-aspartate receptors in rat hippocampal neurons.

Aracava Y, Pereira EF, Maelicke A, Albuquerque EX.

J Pharmacol Exp Ther. 2005 Mar;312(3):1195-205. Epub 2004 Nov 2.

PMID:
15522999
12.

Spine density and dendritic branching pattern of hippocampal CA1 pyramidal neurons in neonatal rats chronically exposed to the organophosphate paraoxon.

Santos HR, Cintra WM, Aracava Y, Maciel CM, Castro NG, Albuquerque EX.

Neurotoxicology. 2004 Mar;25(3):481-94.

PMID:
15019311
13.

Design, synthesis, and pharmacological profile of novel fused pyrazolo[4,3-d]pyridine and pyrazolo[3,4-b][1,8]naphthyridine isosteres: a new class of potent and selective acetylcholinesterase inhibitors.

Barreiro EJ, Camara CA, Verli H, Brazil-Más L, Castro NG, Cintra WM, Aracava Y, Rodrigues CR, Fraga CA.

J Med Chem. 2003 Mar 27;46(7):1144-52.

PMID:
12646025
14.

Low concentrations of pyridostigmine prevent soman-induced inhibition of GABAergic transmission in the central nervous system: involvement of muscarinic receptors.

Santos MD, Pereira EF, Aracava Y, Castro NG, Fawcett WP, Randall WR, Albuquerque EX.

J Pharmacol Exp Ther. 2003 Jan;304(1):254-65.

PMID:
12490599
15.

The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system.

Santos MD, Alkondon M, Pereira EF, Aracava Y, Eisenberg HM, Maelicke A, Albuquerque EX.

Mol Pharmacol. 2002 May;61(5):1222-34.

PMID:
11961141
16.

A novel thienylhydrazone, (2-thienylidene)3,4-methylenedioxybenzoylhydrazine, increases inotropism and decreases fatigue of skeletal muscle.

Gonzalez-Serratos H, Chang R, Pereira EF, Castro NG, Aracava Y, Melo PA, Lima PC, Fraga CA, Barreiro EJ, Albuquerque EX.

J Pharmacol Exp Ther. 2001 Nov;299(2):558-66.

PMID:
11602667
17.
18.

Direct inhibition of the N-methyl-D-aspartate receptor channel by dopamine and (+)-SKF38393.

Castro NG, de Mello MC, de Mello FG, Aracava Y.

Br J Pharmacol. 1999 Apr;126(8):1847-55.

19.

An analysis of low level doses of cholinesterase inhibitors in cultured neurons and hippocampal slices of rats.

Rocha ES, Chebabo SR, Santos MD, Aracava Y, Albuquerque EX.

Drug Chem Toxicol. 1998;21 Suppl 1:191-200.

PMID:
10028411
20.

Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization and modulation of synaptic function.

Albuquerque EX, Alkondon M, Pereira EF, Castro NG, Schrattenholz A, Barbosa CT, Bonfante-Cabarcas R, Aracava Y, Eisenberg HM, Maelicke A.

J Pharmacol Exp Ther. 1997 Mar;280(3):1117-36. No abstract available.

PMID:
9067295
21.

Methamidophos: an anticholinesterase without significant effects on postsynaptic receptors or transmitter release.

Camara AL, Braga MF, Rocha ES, Santos MD, Cortes WS, Cintra WM, Aracava Y, Maelicke A, Albuguergue EX.

Neurotoxicology. 1997;18(2):589-602.

PMID:
9291508
22.

Glycine and calcium-dependent effects of lead on N-methyl-D-aspartate receptor function in rat hippocampal neurons.

Marchioro M, Swanson KL, Aracava Y, Albuquerque EX.

J Pharmacol Exp Ther. 1996 Oct;279(1):143-53.

PMID:
8858987
23.

Paraoxon: cholinesterase-independent stimulation of transmitter release and selective block of ligand-gated ion channels in cultured hippocampal neurons.

Rocha ES, Swanson KL, Aracava Y, Goolsby JE, Maelicke A, Albuquerque EX.

J Pharmacol Exp Ther. 1996 Sep;278(3):1175-87.

PMID:
8819500
24.

Ligand-gated ion channels in acutely dissociated rat hippocampal neurons with long dendrites.

Barbosa CT, Alkondon M, Aracava Y, Maelicke A, Albuquerque EX.

Neurosci Lett. 1996 Jun 7;210(3):177-80.

PMID:
8805124
25.

Pyrazole, an alcohol dehydrogenase inhibitor, has dual effects on N-methyl-D-aspartate receptors of hippocampal pyramidal cells: agonist and noncompetitive antagonist.

Pereira EF, Aracava Y, Aronstam RS, Barreiro EJ, Albuquerque EX.

J Pharmacol Exp Ther. 1992 Apr;261(1):331-40.

PMID:
1313873
26.

Functional properties of the nicotinic and glutamatergic receptors.

Albuquerque EX, Costa AC, Alkondon M, Shaw KP, Ramoa AS, Aracava Y.

J Recept Res. 1991;11(1-4):603-25.

PMID:
1715922
27.

Sensitivity of N-methyl-D-aspartate (NMDA) and nicotinic acetylcholine receptors to ethanol and pyrazole.

Aracava Y, Fróes-Ferrão MM, Pereira EF, Albuquerque EX.

Ann N Y Acad Sci. 1991;625:451-72. No abstract available.

PMID:
1711814
28.

The anticonvulsant MK-801 interacts with peripheral and central nicotinic acetylcholine receptor ion channels.

Ramoa AS, Alkondon M, Aracava Y, Irons J, Lunt GG, Deshpande SS, Wonnacott S, Aronstam RS, Albuquerque EX.

J Pharmacol Exp Ther. 1990 Jul;254(1):71-82.

PMID:
1694895
29.

Activation and blockade of the acetylcholine receptor-ion channel by the agonists (+)-anatoxin-a, the N-methyl derivative and the enantiomer.

Kofuji P, Aracava Y, Swanson KL, Aronstam RS, Rapoport H, Albuquerque EX.

J Pharmacol Exp Ther. 1990 Feb;252(2):517-25.

PMID:
1690292
30.

Molecular effects of dimethylanatoxin on the peripheral nicotinic acetylcholine receptor.

Costa AC, Swanson KL, Aracava Y, Aronstam RS, Albuquerque EX.

J Pharmacol Exp Ther. 1990 Feb;252(2):507-16.

PMID:
1690291
31.

Agonist recognition site of the peripheral acetylcholine receptor ion channel complex differentiates the enantiomers of nicotine.

Rozental R, Aracava Y, Scoble GT, Swanson KL, Wonnacott S, Albuquerque EX.

J Pharmacol Exp Ther. 1989 Nov;251(2):395-404.

PMID:
2478693
32.

N-methylanatoxinol isomers: derivatives of the agonist (+)-anatoxin-a block the nicotinic acetylcholine receptor ion channel.

Swanson KL, Aracava Y, Sardina FJ, Rapoport H, Aronstam RS, Albuquerque EX.

Mol Pharmacol. 1989 Feb;35(2):223-31.

PMID:
2465486
33.

Structure-activity relationship of reversible cholinesterase inhibitors: activation, channel blockade and stereospecificity of the nicotinic acetylcholine receptor-ion channel complex.

Albuquerque EX, Aracava Y, Cintra WM, Brossi A, Schönenberger B, Deshpande SS.

Braz J Med Biol Res. 1988;21(6):1173-96. Review.

PMID:
3074841
34.

Nicotinic acetylcholine receptors in cultured neurons from the hippocampus and brain stem of the rat characterized by single channel recording.

Aracava Y, Deshpande SS, Swanson KL, Rapoport H, Wonnacott S, Lunt G, Albuquerque EX.

FEBS Lett. 1987 Sep 28;222(1):63-70.

35.

The molecular basis of anticholinesterase actions on nicotinic and glutamatergic synapses.

Aracava Y, Deshpande SS, Rickett DL, Brossi A, Schönenberger B, Albuquerque EX.

Ann N Y Acad Sci. 1987;505:226-55. No abstract available.

PMID:
2446549
36.

Noncompetitive blockade of the nicotinic acetylcholine receptor-ion channel complex by an irreversible cholinesterase inhibitor.

Rao KS, Aracava Y, Rickett DL, Albuquerque EX.

J Pharmacol Exp Ther. 1987 Jan;240(1):337-44.

PMID:
2433427
37.
38.

Multiple actions of anticholinesterase agents on chemosensitive synapses: molecular basis for prophylaxis and treatment of organophosphate poisoning.

Albuquerque EX, Deshpande SS, Kawabuchi M, Aracava Y, Idriss M, Rickett DL, Boyne AF.

Fundam Appl Toxicol. 1985 Dec;5(6 Pt 2):S182-203.

PMID:
2868960
39.

The reversible cholinesterase inhibitor physostigmine has channel-blocking and agonist effects on the acetylcholine receptor-ion channel complex.

Shaw KP, Aracava Y, Akaike A, Daly JW, Rickett DL, Albuquerque EX.

Mol Pharmacol. 1985 Dec;28(6):527-38.

PMID:
2417099
40.

The acetylcholine receptor of the neuromuscular junction recognizes mecamylamine as a noncompetitive antagonist.

Varanda WA, Aracava Y, Sherby SM, VanMeter WG, Eldefrawi ME, Albuquerque EX.

Mol Pharmacol. 1985 Aug;28(2):128-37.

PMID:
2410768
42.

Interactions of bupivacaine with ionic channels of the nicotinic receptor. Analysis of single-channel currents.

Aracava Y, Ikeda SR, Daly JW, Brookes N, Albuquerque EX.

Mol Pharmacol. 1984 Sep;26(2):304-13.

PMID:
6090885
43.

Interactions of bupivacaine with ionic channels of the nicotinic receptor. Electrophysiological and biochemical studies.

Ikeda SR, Aronstam RS, Daly JW, Aracava Y, Albuquerque EX.

Mol Pharmacol. 1984 Sep;26(2):293-303.

PMID:
6090884
44.

Effects of amphotericin B on membrane permeability--kinetics of spin probe reduction.

Aracava Y, Schreier S, Phadke R, Deslauriers R, Smith IC.

Biophys Chem. 1981 Dec;14(4):325-32.

PMID:
6279197
45.

Effect of amphotericin B on membranes: a spin probe study.

Aracava Y, Smith IC, Schreier S.

Biochemistry. 1981 Sep 29;20(20):5702-7.

PMID:
6271190
46.

Supplemental Content

Loading ...
Support Center